Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Diseases, Obstructive: early-phase trial registry
1 of 7 indexed Lung Diseases, Obstructive trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Lung Diseases, Obstructive: 7 US clinical trials tracked, 1 recruiting.
Lung Diseases, Obstructive is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is David Van Sickle, running 1 of these trials.
Enrollment posture brief
Registry condition lung-diseases-obstructive
OPEN 1 | RECR 14% | LATE 1 | EARLY 2 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Lung Diseases, Obstructive lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Diseases, Obstructive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Diseases, Obstructive is recruiting below its size-band peers.
1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lung Diseases, Obstructive trials is spread across many organizations.
David Van Sickle accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Lung Diseases, Obstructive enrolment sits around 100 participants.
Median target enrolment is 100 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
Lung Diseases, Obstructive research is mostly interventional.
5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Cough Capture as a Portal Into the Lung
Albert Einstein College of Medicine
NCT05854563
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
Pfizer
NCT00808288
Study of Acid Reflux in Asthma
Johns Hopkins Bloomberg School of Public Health
NCT00069823
The Leaky Lung Test
University of Rochester
NCT02306473
Asthma Data Innovation Demonstration Project
David Van Sickle
NCT02162576
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
University of Michigan
NCT00281242
A Phase I Study of iPS Cell Generation From Patients With COPD
Mayo Clinic
NCT01860898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Diseases, Obstructive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Diseases, Obstructive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Diseases, Obstructive page
7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Lung Diseases, Obstructive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- David Van Sickle sponsors the most Lung Diseases, Obstructive trials on record, review their full trial history before evaluating a specific study. See David Van Sickle's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Diseases, Obstructive condition card totals 7 registered trials; most-linked intervention Placebo proton pump inhibitor; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.